FDA Tosses Par Pharma's Anti-Generic Bid, Vows FTC Referral
The U.S. Food and Drug Administration has shot down Par Pharmaceutical's bid to keep a rival generic of its flagship drug off the market, even going so far as to say...To view the full article, register now.
Already a subscriber? Click here to view full article